Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2020
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2020
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Myelocytic Leukemia - Pipeline Review, H1 2020, provides an overview of the Acute Myelocytic Leukemia (Oncology) pipeline landscape.
Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the blood stream and spread to the other parts of the body. Symptoms for AML include fatigue, fever, bleeding, breathing problems, weight loss. The predisposing factors involved are exposure to radiation or chemicals and smoking. Treatment includes chemotherapy, transfusions, transplant and surgery.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Myelocytic Leukemia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Acute Myelocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Acute Myelocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 3, 17, 137, 137, 2, 7, 236, 44 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 18, 20, 5, 1, 48 and 27 molecules, respectively.
Acute Myelocytic Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (Oncology).
- The pipeline guide reviews pipeline therapeutics for Acute Myelocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acute Myelocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acute Myelocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Acute Myelocytic Leukemia (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acute Myelocytic Leukemia (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acute Myelocytic Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Introduction
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Overview
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Development
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Assessment
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Companies Involved in Therapeutics Development
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Drug Profiles
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Product Development Milestones
Appendix
Tables and Figures
List of Tables
Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by 4SC AG, H1 2020
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2020
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AB Science SA, H1 2020
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AbbVie Inc, H1 2020
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ABL Bio Inc, H1 2020
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Accent Therapeutics Inc, H1 2020
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Acepodia Biotech Inc, H1 2020
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Acrotech Biopharma LLC, H1 2020
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Actinium Pharmaceuticals Inc, H1 2020
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Adlai Nortye Biopharma Co Ltd, H1 2020
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Advanced BioDesign, H1 2020
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Advenchen Laboratories LLC, H1 2020
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aeglea BioTherapeutics Inc, H1 2020
Companies Mentioned
4SC AG
A. Menarini Industrie Farmaceutiche Riunite Srl
AB Science SA
AbbVie Inc
ABL Bio Inc
Accent Therapeutics Inc
Acepodia Biotech Inc
Acrotech Biopharma LLC
Actinium Pharmaceuticals Inc
Adlai Nortye Biopharma Co Ltd
Advanced BioDesign
Advenchen Laboratories LLC
Aeglea BioTherapeutics Inc
Affichem SA
Agenus Inc
Agios Pharmaceuticals Inc
AI Therapeutics
Aileron Therapeutics Inc
AIMM Therapeutics BV
Aleta Biotherapeutics Inc
Alfasigma SpA
Allogene Therapeutics Inc
Amgen Inc
Amphivena Therapeutics Inc
Amplia Therapeutics Ltd
Angiocrine Bioscience Inc
Anhui Anke Biotechnology (Group) Co Ltd
ANP Technologies Inc
Antengene Corp
Antisense Therapeutics Ltd
AnyGen Co Ltd
APIM Therapeutics AS
Aprea Therapeutics AB
AptaBio Therapeutics Inc
Aptevo Therapeutics Inc
Aptose Biosciences Inc
Aravive Inc
Arcellx Inc
Argenx SE
Arog Pharmaceuticals Inc
Arrien Pharmaceuticals LLC
Arvinas Inc
Ascentage Pharma Group International
Aslan Pharmaceuticals Ltd
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
Athenex Inc
ATP Biopharm
AUM Biosciences Pte Ltd
Auransa Inc
Aurigene Discovery Technologies Ltd
Avidin Ltd
AVROBIO Inc
Avvinity Therapeutics Ltd
Bantam Pharmaceutical LLC
Bayer AG
BCI Pharma SA
Beam Therapeutics Inc
Beijing Immunochina Medical Science & Technology Co Ltd
Bellicum Pharmaceuticals Inc
BerGenBio ASA
Betta Pharmaceuticals Co Ltd
Bio-Cancer Treatment International Ltd
Bio-Path Holdings Inc
Biokine Therapeutics Ltd
BioLineRx Ltd
BioMed Valley Discoveries Inc
Bionomics Ltd
BioSight Ltd
BioTheryX Inc
BioXcel Therapeutics Inc
BiVictriX Therapeutics Ltd
bluebird bio Inc
Blueprint Medicines Corp
Boehringer Ingelheim International GmbH
Boryung ViGenCell Inc
Boston Biomedical Inc
BoYen Therapeutics Inc
Bridge Medicines LLC
Bristol-Myers Squibb Co
Canqura Oncology AB
Cardiff Oncology Inc
Carrick Therapeutics UK Ltd
Catalent Inc
CellCentric Ltd
Cellectis SA
Cellerant Therapeutics Inc
Cellipse SAS
Cellular Biomedicine Group Inc
Celularity Inc
Celyad Oncology
Centrose LLC
Changzhou Qianhong Bio-Pharma Co Ltd
CharlestonPharma LLC
Checkpoint Therapeutics Inc
Chimerix Inc
Chongqing Precision Biotech Co Ltd
Chordia Therapeutics Inc
Chugai Pharmaceutical Co Ltd
Clear Creek Bio Inc
Cleave Therapeutics Inc
CoImmune Inc
Constellation Pharmaceuticals Inc
CRISPR Therapeutics AG
CrystalGenomics Inc
CSPC Pharmaceutical Group Ltd
Cue Biopharma Inc
Cullinan Oncology LLC
CuronBiotech Inc
Cyclacel Pharmaceuticals Inc
Cytovia Inc
Daiichi Sankyo Co Ltd
Dalriada Therapeutics Inc
DC Prime BV
Deciphera Pharmaceuticals Inc
Delta-Fly Pharma Inc
Demuris Ltd
Denovo Biopharma LLC
DiNonA Inc
Dong-A ST Co Ltd
Eli Lilly and Co
Emercell SAS
Eminent Biosciences
EntreChem SL
Enzyme by Design Inc
Epigene Therapeutics Inc
Epizyme Inc
Escend Pharmaceuticals Inc
ExCellThera Inc
Exonate Ltd
Expression Therapeutics LLC
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Fimecs Inc
Flavocure Biotech LLC
Forma Therapeutics Inc
Fujifilm Holdings Corp
Gadeta BV
Gamida Cell Ltd
GC Pharma
GEMoaB Monoclonals GmbH
Genentech Inc
Genmab AS
Genosco Inc
Genus Oncology LLC
Geron Corp
Gilead Sciences Inc
GlaxoSmithKline Plc
GlycoMimetics Inc
Glycostem Therapeutics BV
GO Therapeutics Inc
Golden Biotechnology Corp
GT Biopharma Inc
H3 Biomedicine Inc
Hanmi Pharmaceuticals Co Ltd
Hebei Senlang Biotechnology Inc Ltd
HEC Pharm Co Ltd
Hefei Cosource Pharmaceutical Inc
Helocyte Biosciences Inc
HemoGenyx LLC
HemoGenyx Pharmaceuticals Plc
HiFiBiO SAS
HighPass Bio Inc
Hillstream BioPharma Inc
Hinova Pharmaceuticals Inc
Hoverink Biotechnologies Inc
HRAIN Biotechnology Co Ltd
Hummingbird Bioscience Pte Ltd
Hunan Siweikang Therapeutics Ltd
Hutchison MediPharma Ltd
Hybrigenics SA
I-Mab Biopharma Co Ltd
iCell Gene Therapeutics LLC
IGF Oncology LLC
IGM Biosciences Inc
Imago BioSciences Inc
ImCheck Therapeutics SAS
Immune Onc Therapeutics Inc
Immune System Key Ltd
ImmunoGen Inc
Immunomedics Inc
Inatherys
Incuron LLC
Incysus Therapeutics Inc
Incyte Corp
Inflection Biosciences Ltd
Inmune Bio Inc
Innovation Pharmaceuticals Inc
Intellia Therapeutics Inc
Interprotein Corp
Intra-Immusg Pvt Ltd
Io Therapeutics Inc
Iterion Therapeutics
Jasper Therapeutics Inc
Jazz Pharmaceuticals Plc
Jeil Pharmaceutical Co Ltd
Jiangsu Aidea Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
JSK Therapeutics Inc
Jubilant Therapeutics Inc
Juno Therapeutics Inc
Juventas Cell Therapy Ltd
JW Pharmaceutical Corp
Kainos Medicine Inc
Kartos Therapeutics Inc
Karyopharm Therapeutics Inc
Keystone Nano Inc
Kiadis Pharma NV
KinaRx LLC
KisoJi Biotechnology Inc
Komipharm International Co Ltd
Konruns Pharmaceutical Co Ltd
Kura Oncology Inc
Kurome Therapeutics Inc
Kymera Therapeutics LLC
Laekna Therapeutics Shanghai Co Ltd
Lai Corporation Pty Ltd
Lead Discovery Center GmbH
Les Laboratoires Servier SAS
Leukos Biotech SL
Lineage Cell Therapeutics Inc
Lumos Pharma Inc
Mablink Bioscience
Machavert Pharmaceuticals LLC
MacroGenics Inc
Magenta Therapeutics Inc
Mana Therapeutics Inc
Marker Therapeutics Inc
Mateon Therapeutics Inc
Maxinovel Pharmaceuticals
MedAbome Inc
MediGene AG
Medivir AB
MEI Pharma Inc
Merck & Co Inc
Merck KGaA
Merus NV
Meryx Inc
Millennium Pharmaceuticals Inc
Minneamrita Therapeutics LLC
Miragen Therapeutics Inc
MiRx Pharmaceuticals LLC
Molecular Templates Inc
Molecules For Health Inc
Moleculin Biotech LLC
MolMed SpA
Multitude therapeutics Inc
Mustang Bio Inc
MyeloRx LLC
Nanjing Iaso Biotherapeutics Co Ltd
Nanjing Legend Biotech Co Ltd
Nanjing Sanhome Pharmaceutical Co Ltd
Nanovalent Pharmaceuticals Inc
NantKwest Inc
Nemucore Medical Innovations Inc
Newave Pharmaceutical Inc
NexImmune Inc
Nkarta Inc
NMS Group SpA
Nohla Therapeutics Inc
Northlake International LLC
Novartis AG
OHM Oncology
Omeros Corp
Oncoceutics Inc
Oncoheroes Biosciences Inc
OncoImmune Inc
Oncopeptides AB
OncoTartis Inc
OncoTherapy Science Inc
Oncternal Therapeutics
Ono Pharmaceutical Co Ltd
Opsyon
Orano Med LLC
Orca Biosystems Inc
Orsenix Holdings BV
Oryzon Genomics SA
Otsuka Holdings Co Ltd
Oxford BioTherapeutics Ltd
Oxstem Ltd
Pacylex Pharmaceuticals Inc
PentixaPharm GmbH
Peptron Inc
PersonGen Biomedicine Suzhou Co Ltd
Petra Pharma Corp
Pfizer Inc
Pharma Mar SA
Pharos I&BT Co Ltd
Phebra Pty Ltd
Phi Pharma SA
Philogen SpA
PhoreMost Ltd
Picobella LLC
Pimera Inc
PiNK Biopharma Ltd
Pinotbio Inc
Pinteon Therapeutics Inc
Plexxikon Inc
PRISM Pharma Co Ltd
Promutech Pharmaceuticals Inc
Protheragen Inc
Provectus Biopharmaceuticals Inc
Provention Bio Inc
PTC Therapeutics Inc
PYCTX Ltd
Qualigen Therapeutics Inc
Qurient Co Ltd
Race Oncology Ltd
Rafael Pharmaceuticals Inc
Rasna Therapeutics Inc
Regenacy Pharmaceuticals LLC
Rhizen Pharmaceuticals SA
Rich Pharmaceuticals Inc
Rubius Therapeutics Inc
Ryvu Therapeutics SA
Salarius Pharmaceuticals Inc
Samumed LLC
Sandhill Therapeutics Inc
Sanofi
Sapience Therapeutics Inc
Sareum Holdings Plc
Seattle Genetics Inc
SELLAS Life Sciences Group Inc
Senhwa Biosciences Inc
SFA Therapeutics LLC
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Shanghai icell Biotechnology Co Ltd
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Shijiazhuang Yiling Pharmaceutical Co Ltd
SignalChem Lifesciences Corp
Sino Biopharmaceutical Ltd
SiNOPSEE Therapeutics Pte Ltd
SL Bigen Inc
SMET Pharmaceutical Inc
Solasia Pharma KK
SpecificiT Pharma Inc
Spectrum Pharmaceuticals Inc
AIkido Pharma Inc
SphingoGene Inc
Stelexis Therapeutics LLC
Storm Therapeutics Ltd
Sumitomo Dainippon Pharma Co Ltd
Sunesis Pharmaceuticals Inc
Surface Oncology Inc
SuviCa Inc
Suzhou Zelgen Biopharmaceutical Co Ltd
Synactix Pharmaceuticals Inc
Syndax Pharmaceuticals Inc
SYNIMMUNE GmbH
Tacitus Therapeutics Inc
TaiGen Biotechnology Co Ltd
Takara Bio Inc
Takeda Pharmaceutical Co Ltd
TC BioPharm Ltd
TeamedOn International LLC
Teva Pharmaceutical Industries Ltd
TheraPharm Deutschland GmbH
Tiziana Life Sciences Plc
Tmunity Therapeutics Inc
Toko Pharmaceutical Industries Co Ltd
Tolero Pharmaceuticals Inc
TOLREMO Therapeutics AG
TOT Biopharm Co Ltd
Treadwell Therapeutics Inc
Trillium Therapeutics Inc
Triphase Accelerator Corp
UbiVac LLC
Vertex Pharmaceuticals Inc
Veru Inc
Vessel Scientific LLC
Vichem Chemie Research Ltd
VioQuest Pharmaceuticals Inc (Inactive)
Viralytics Pty Ltd
VM Discovery Inc
Vor BioPharma Inc
Vyriad Inc
Wugen Inc
Wuhan Bio-Raid Biotechnology Co Ltd
XEME BioPharma Inc
Xencor Inc
Y-Biologics Inc
Y-mAbs Therapeutics Inc
Yungjin Pharm Co Ltd
Zenith Epigenetics Ltd
Zentalis Pharmaceuticals LLC
ZIOPHARM Oncology Inc
Zovis Pharmaceuticals
Reason to Buy
- Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Pharma & Healthcare Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets